Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer

Leggi l'articolo originale


Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.

Lascia un commento